Sign In
Buy ARKG
$33.15
-0.260 (-0.778%)
At Close: Jun 08, 2026
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
07:57am, Saturday, 25'th Jan 2025
I maintain a buy rating on ARK Genomic Revolution ETF (ARKG) due to improving momentum, potential lower interest rates, and a favorable M&A environment in 2025. Despite a 20% decline in 2024, ARKG's t
Here Are the 6 Largest Stock Holdings in All of Cathie Wood's ETFs Right Now
08:21am, Wednesday, 22'nd Jan 2025
Asset management company Ark Invest offers nine different investment funds, eight of which are available as exchange-traded funds, or ETFs. They all have a different tech-related focus, such as roboti
Best-Performing ETF Areas of Last Week
09:01am, Tuesday, 03'rd Dec 2024
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
Interest Rate Regimes And ARKG: Underperformance Explained
08:00am, Tuesday, 08'th Oct 2024
ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed signific
Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.
04:52am, Tuesday, 27'th Aug 2024
Ark Funds pull exclusively from different slivers of the technology sector that also tend to be the most volatile. Economic conditions can make a bigger performance difference over the long term than
5 Technology ETFs at the Forefront of the August Rebound
11:01am, Tuesday, 20'th Aug 2024
Wall Street roared back after a sell-off early in the month as fears of recession eased. The technology sector, which bore the biggest brunt, rebounded strongly and once again led the market over the
5 Sector ETFs That Outperformed With Double-Digit Gains in July
12:00pm, Thursday, 01'st Aug 2024
July witnessed the "Great Rotation" in the U.S. stock market as investors shunned the hot technology stocks in favor of smaller companies and other sectors, which are the bigger beneficiaries of the F
Best ETFs of Last Week
09:01am, Monday, 29'th Jul 2024
Wall Street offered a mixed performance last week.
ARKG: A Genomics Play But Active Isn't Adding Value
01:07am, Monday, 24'th Jun 2024
Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's ac
BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada
08:00am, Friday, 14'th Jun 2024
TORONTO--(BUSINESS WIRE)---- $ARKG #Cboe--Cboe Canada is pleased to announce BMO has transferred three BMO mutual fund ETF series, trading under the symbols ARKK, ARKW, and ARKG to Cboe Canada.
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
04:28pm, Thursday, 02'nd May 2024
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?
05:43am, Monday, 22'nd Apr 2024
There are better ways to approach innovation than the Ark Innovation ETF. The ARK Space Exploration & Innovation ETF is a balanced bet.
Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
08:01am, Thursday, 04'th Apr 2024
At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.
ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons
05:22am, Monday, 25'th Mar 2024
ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a r
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
04:50am, Monday, 25'th Mar 2024
Cathie Wood's Ark Genomic Innovation ETF has exited its position in Pfizer. Wood is likely disappointed with Pfizer's stock performance and its obesity drug setbacks.
